Shares of Prime Medicine, Inc. (PRME) have gained 24.1% over the past four weeks to close the last trading session at 6.54,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof14.45 indicates a potential upside of 121%. The average comprises 11 short-term price targets ranging from a low of 9toahighof21, with a standard deviation of $4.34. While the lowest estimate indicate ...